Why the growth investor may take a look at NASDAQ:CPRX.

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is suited for growth investing. Investors should of couse do their own research, but we spotted CATALYST PHARMACEUTICALS INC showing up in our CANSLIM growth screen, so it may be worth spending some more time on it.

What matters for canslim investors.

• With a favorable trend in its quarter-to-quarter (Q2Q) earnings per share (EPS), CATALYST PHARMACEUTICALS INC highlights its ability to generate increasing profitability, showcasing a 65.0% growth.
• With consistent quarter-to-quarter (Q2Q) revenue growth of 87.49%, CATALYST PHARMACEUTICALS INC exemplifies its ability to generate increased sales and revenue streams. This growth signifies the company's strong business performance and its potential for continued growth.
• The EPS of CATALYST PHARMACEUTICALS INC has shown consistent growth over a 3-year period, indicating the company's ability to generate increasing earnings over time.
• In terms of Return on Equity(ROE), CATALYST PHARMACEUTICALS INC is performing well, achieving a 30.79% ratio. This highlights the company's effective allocation of shareholder investments and signifies its commitment to maximizing returns.
• The Relative Strength (RS) of CATALYST PHARMACEUTICALS INC has consistently been strong, with a current 84.92 rating. This indicates the stock's ability to exhibit relative price outperformance and reflects its competitive strength. CATALYST PHARMACEUTICALS INC demonstrates promising potential for sustained price momentum.
• With a Debt-to-Equity ratio at 0.0, CATALYST PHARMACEUTICALS INC showcases its prudent financial management. The company's balanced approach between debt and equity reflects its commitment to maintaining a stable capital structure.
• CATALYST PHARMACEUTICALS INC exhibits a favorable ownership structure, with an institutional shareholder ownership of 77.59%. This signifies a diverse investor base, which can contribute to a more stable and efficient market for the stock.

What is the technical picture of NASDAQ:CPRX telling us.

As part of its analysis, ChartMill provides a comprehensive Technical Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various technical indicators and properties.

Taking everything into account, CPRX scores 5 out of 10 in our technical rating. CPRX has been an average performer in the overall market. Recently some decent action could be observed, but in the medium term time frame this is still negative.

• CPRX is part of the Biotechnology industry. There are 617 other stocks in this industry. CPRX outperforms 83% of them.
• Both the short term and long term trends are neutral. So this is not the most entertaining stock around.
• Looking at the yearly performance, CPRX did better than 84% of all other stocks. However, this relatively good performance is mostly due to a recent big move.
• In the last month CPRX has a been trading in the 13.22 - 15.59 range, which is quite wide. It is currently trading in the middle of this range, so some resistance may be found above.

Our latest full technical report of CPRX contains the most current technical analsysis.

A complete fundamental analysis of NASDAQ:CPRX

Every day ChartMill assigns a Fundamental Rating to every stock. The score ranges from 0 to 10 and is determined by evaluating multiple fundamental indicators and properties.

CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 617 industry peers in the Biotechnology industry. CPRX gets an excellent profitability rating and is at the same time showing great financial health properties. CPRX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make CPRX suitable for value and growth and quality investing!

Our latest full fundamental report of CPRX contains the most current fundamental analsysis.

Our CANSLIM screen will find you more ideas suited for growth investing.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.